Answers are grounded in this paper and cite their sources.
PURPOSE AND EXPERIMENTAL DESIGN: To test whether plasminogen activator inhibitor-1 (PAI-1) can serve as a candidate marker for the malignancy of esophageal squamous cell carcinoma (SCC), we performed a quantitative reverse transcription-PCR for PAI-1 gene and evaluated the possible relationship between PAI-1 gene expression levels and clinicopathological findings in esophageal SCC. RESULTS: Significant increases in PAI-1 scores were observed in metastasis-positive esophageal SCCs (3.08 +/- 0.80) compared with metastasis-negative ones (-0.31 +/- 0.62; P = 0.0042). PAI-1 expression scores significantly increased with tumor stage (P = 0.05, ANOVA). CONCLUSIONS: These results suggested that PAI-1 might serve as a new parameter for prediction of prognosis in esophageal SCC.
No takes yet. Share an insight, caveat, or question.
Sakakibara et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: